anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: To investigate shared versus distinct differences in brain structure among children with ADHD and obesity, we examined the morphology of regions implicated in cognitive control and reward function in a single cross-sectional cohort of children with and without ADHD and overweight/obesity (OV/OB).
METHOD: Participants included 471 children ages 8-12 years with ADHD (n = 244; 58 OV/OB) and neurotypical (NT) controls (n = 227; 81 OV/OB) classified as healthy-weight (HW; BMI %ile 5th to <85th) vs. having OV/OB (BMI %ile≥85th). Structural MRI was performed to obtain measures of cortical and subcortical morphology and compared across ADHD × BMI groups.
RESULTS: Surface area was generally lower in ADHD vs. NT including in anterior cingulate cortex (ACC), dorsolateral prefrontal cortex (dlPFC), medial (m)PFC, and primary motor (M1) cortex. In contrast, cortical thickness was generally lower in OV/OB vs. HW for ACC, dlPFC, orbitofrontal cortex (OFC), mPFC, and supplementary motor cortex (SMC). Furthermore, ADHD × OV/OB interactions were observed for the ACC and OFC, with the lowest ACC volume in the ADHD + OV/OB group and the highest OFC surface area in the NT + OV/OB group. Subcortical volumes did not differ between groups.
CONCLUSIONS: Our findings reveal distinct alterations in cortical morphology in association with ADHD and overweight, with cortical surface area reduced in ADHD vs. thickness reduced in OV/OB. Additionally, the findings provide evidence of combined effects of ADHD × OV/OB in brain regions integral to cognition and motivation. Our results support further investigation of causes and correlates of shared and distinct ADHD- and OV/OB-associated differences in developing frontocingulate morphology.
Progression of lung disease in patients with Alpha-1 Anti-trypsin deficiency is variable and while some patients may have stable lung function over many years, some progress and deteriorate rapidly. Currently there are no predictors that would help identify patient at risk of rapid deterioration in the PiMZ patient population. The aim of this study is to identify markers and features in CT imaging that may allow identification of these patients early before deterioration. To achieve this, the study will follow a cohort of patients with confirmed Alpha-1 Anti-trypsin deficiency (MZ genotype) and obstructive lung disease and measure a number of biomarkers in blood and sputum and obtain high resolution CT scans at baseline and again three years later. If the study is able to determine markers that allow the identification of patients at risk early, the investigator may be able to study early interventions in later studies and possibly find ways to avoid serious complications. Patients will be followed longitudinally to assess deterioration of lung function.

Study procedures include: Review of medical history and medication history, blood draw, spriometry, induced sputum (at some sites), completion of questionnaires and CT Chest scan. All of the mentioned procedures above will be performed on enrollment and repeated at 18 months and 36 months, with the exception of monthly Alpha- net exacerbation questionnaires.
The application is an invention patient divisional application which is applied on January 11, 2011 with the application number 201110004638.9 and is named 'a compound medicinal composition for improving the oral bioavailability of paclitaxel and an application thereof'. The invention discloses a compound medicinal composition for improving the oral bioavailability of paclitaxel and an application thereof. The invention further discloses a medicinal composition containing the compound medicinal composition and a paclitaxel monomer compound. The compound medicinal compound disclosed by the invention can be used for improving the oral bioavailability of the paclitaxel, and can contribute to enhancing the antic-cancer effect of the paclitaxel when used for preparing an anti-cancer medicament. In the compound medicinal composition, the paclitaxel is taken as a main anti-cancer component, and the Chinese medicine-extracted monomer compound is used for restraining the first pass effect of the paclitaxel, so that the oral bioavailability and anti-cancer effect of the paclitaxel are improved. As proved by experimental research, the compound medicinal composition is prepared into an oral medicament, and the blood concentration and anti-cancer effect of orally-taken paclitaxel can be improved.
A standard 3+3 dose escalation format will be used. Capecitabine will start at 850mg/m2 to be given on days 1-14 and off days 15-21. If tolerated, the dose will then be escalated to 1000mg/m2 for the next cohort, given on the same schedule. The dose of aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. The website offers a school-wide approach to preventing and managing sports concussion, including a) training for educators, athletics staff, students, and parents; b) guidelines for creating a concussion management team; and c) information on strategies for supporting students in the classroom following concussion.
A surgical resection is currently the preferred treatment for esophageal cancer if the tumor is considered to be resectable without evidence of distant metastases. A higher percentage of radical resection is reported in studies using neoadjuvant chemotherapy followed by surgery versus surgery alone. The neoadjuvant chemotherapy may improve overall survival. Neoadjuvant chemotherapy with administrations of paclitaxel combined with cisplatin or carboplatin has shown effectively. Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR). The clinical phase I study of the combination of Nimotuzumab administered concurrently with chemo-irradiation in patients with local advanced esophageal squamous cell carcinoma has shown the safety and the potential efficacy of Nimotuzumab. The concurrent trial is a clinical phase II trial designed to assess the efficacy of the combination of Nimotuzumab administered concurrently with neoadjuvant chemotherapy in patients with resectable Esophageal Squamous Cell Carcinoma, and to further investigate its side-effect and toxicity.
Improved ointment or suppository bases are produced by (1) heating them (before or after the addn. of active ingredients and, opt., adjuvants) to above the melting or solidification point; (ii) removing the dissolved oxygen by evacuation; (iii) subsequently saturating the molten mass with an inert gas; and (iv) cooling to below the melting or solidification point. The bases contain 1% dissolved oxygen, and are otherwise satd. with an inert gas. The bases protect oxygen-sensitive active substances against oxidative degradation. In an example regarding prodn. of phenylbutazone suppositories, hard fat (4100 g; DAB 7) is melted at 40 degrees C under high-speed stirring and evacuated at 0.1 Torr until no more bubbles appear. The vessel is subsequently filled with N2 at atmos. pres. and stirring is continued 10 mins. Evacuation and nitrogen gassing are repeated twice to give a prod. contg. 0.1 vol. % O2.
Patients in the control practices will receive treatment-as-before, which means that the patients will not be offered the structured SDM process. So the GP will treat the former ADDITION patients as they were used during the period that followed after the ADDITION study (2009), either according to the national guidelines or to the ADDITION intensive treatment algorithm.
Following the initial evaluation to determine eligibility, participants will be enrolled in a baseline phase in which perception and production abilities will be probed but not treated. In a multiple-baseline across-subjects design with randomization, the 10 participants will be randomly assigned to transition from the baseline to the treatment condition at one of 7 possible points, ranging from 4 to 10 baseline sessions. After baseline sessions, perceptual training will be delivered in twelve 30-minute sessions occurring 3 times per week for 4 weeks. The training is fully computerized and can be self-administered, but a study clinician will attend one session per participant per week to ensure attention to study tasks. Each session will feature three listening tasks of approximately equal duration. Following perceptual training, participants will receive 4 60-minute sessions of production training completed over two weeks.
Subjects will be on study for 28 days. Sensor glucose, exercise, insulin and meal data will be collected during this time. Subjects will wear the Dexcom G6 CGM system and a physical activity monitor. The Subjects will complete 2 exercise visits in-clinic and 4 exercise visits as an outpatient. Subjects will be randomized to aerobic, anaerobic or high intensity interval exercise sessions for 30 minutes each. Physicians will review CGM and insulin data every 7 days and make insulin dose recommendations that the subject will adjust in the dose calculator.
Days 1, 9 and 13: Healthy Volunteers will take samatasvir in the mornings under fasted conditions with water or Coke. Days 5-16: Healthy Volunteers will take omeprazole in the mornings under fasted conditions with water or Coke.
248,698. White Dental Manufacturing Co., S. S., (Assignees of Eberly, N. E.). March 3, 1925, [Convention date]. Metallic oxide cements.-A dental cement is produced by fuzing a mixture of silica and aluminium oxide, preferably in the presence of a flux such as calcium fluoride to form a basic glass. This glass is powdered and mixed with a second constituent produced by fusing together basic oxides such as zinc oxide and silica, clay, or magnesia, bismuth oxide, &c., and grinding the mass. The proportions may vary between 70 and 98 per cent of the first powder to 30-2 per cent of the second. The mixture is calcined and ground and moistened with a solution of phosphoric acid in water in which phosphates of zinc, aluminium, &c. are dissolved. The calcination of a miture of 70 per cent of the glass and 30 per cent of a mixture of 95 per cent of zinc oxide and 5 per cent of bismuth oxide may be omitted.
Isoprenaline hydrochloride (IH) is a β-adrenergic receptor agonist commonly used in the treatment of hypotension, shock, asthma, and other diseases. However, IH-induced cardiotoxicity limits its application. A large number of studies have shown that long noncoding RNA (lncRNA) regulates the occurrence and development of cardiovascular diseases. This study aimed to investigate whether abnormal lncRNA expression is involved in IH-mediated cardiotoxicity. First, the Sprague-Dawley (SD) rat myocardial injury model was established. Circulating exosomes were extracted from the plasma of rats and identified. In total, 108 differentially expressed (DE) lncRNAs and 150 DE mRNAs were identified by sequencing. These results indicate that these lncRNAs and mRNAs are substantially involved in chemical cardiotoxicity. Further signaling pathway and functional studies indicated that lncRNAs and mRNAs regulate several biological processes, such as selective mRNA splicing through spliceosomes, participate in sphingolipid metabolic pathways, and play a certain role in the circulatory system. Finally, we obtained 3 upregulated lncRNAs through reverse transcription-quantitative PCR (RT-qPCR) verification and selected target lncRNA-mRNA pairs according to the regulatory relationship of lncRNA/mRNA, some of which were associated with myocardial injury. This study provides valuable insights into the role of lncRNAs as novel biomarkers of chemical-induced cardiotoxicity.
Single am of intervention of ONS, EnergieShake 1.5 kcal Complete, in the open label study are to be given to participants for 8 days, i.e. two bottles twice daily.
Preclinical evidence implicating cannabinoid receptor 2 (CB2) in various diseases has led researchers to question whether CB2 genetics influence aetiology or progression. Associations between conditions and genetic loci are often studied via single nucleotide polymorphism (SNP) prevalence in case versus control populations. In the CNR2 coding exon, ~36 SNPs have high overall population prevalence (minor allele frequencies [MAF] ~37%), including non-synonymous SNP (ns-SNP) rs2501432 encoding CB2 63Q/R. Interspersed are ~27 lower frequency SNPs, four being ns-SNPs. CNR2 introns also harbour numerous SNPs. This review summarises CB2 ns-SNP molecular pharmacology and evaluates evidence from ~70 studies investigating CB2 genetic variants with proposed linkage to disease. Although CNR2 genetic variation has been associated with a wide variety of conditions, including osteoporosis, immune-related disorders, and mental illnesses, further work is required to robustly validate CNR2 disease links and clarify specific mechanisms linking CNR2 genetic variation to disease pathophysiology and potential drug responses.
PROBLEM TO BE SOLVED: To obtain a plaster containing an isosorbide dinitrate (hereinafter referred to as ISDN) capable of suppressing the occurrence of skin rash and excellent in pereutaneous absorption and tackiness and having good sustained release property. SOLUTION: This plaster is obtained by forming a tacky composition containing ISDN on a flexible carrier. The tacky composition comprises (A) a silicone based tacky agent of the formula [Me is CH3 or O-Si(Me)3 ; R' is OH or CH3 ; (x) and (y) are each 50-50000], (B) a polyvinyl acetate-based tacky agent and (C) ISDN. The weight ratio of each component is shown as follows. A:B=(85:15) to (15:85); (A+B):C=(90:10) to (60:40). A tacky agent layer of a mixture-based tacky agent not containing ISDN is obtained and a solution containing ISDN is attached to the tacky agent layer and then, the tacky agent layer to which ISDN is attached is heated or aged and ISDN is incorporated into the tacky agent layer to provide a tacky composition. A carrier obtained by laminating a polyester film, an adhesive layer and a polyester fabric is used as the carrier.
The invention belongs to the field of nursing, and particularly relates to treatment of a forearm ecchymosis hematoma patient after a radial artery interventional operation. The traditional Chinese medicine composition for eliminating ecchymosis comprises the following components: comprises 100-400 parts of safflower, 100-400 parts of salvia miltiorrhiza, 100-400 parts of pseudo-ginseng, 50-250 parts of angelica, 50-250 parts of notopterygium root, 50-250 parts of radix angelicae pubescentis, 20-200 parts of divaricate saposhnikovia root and 20-200 parts of liquorice. The preparation method comprises the following steps: soaking 60% of medicinal materials in 95% ethanol for swelling for 24 hr, placing in a percolation barrel, percolating with 95% ethanol as solvent at flow rate of 2ml/min, and collecting percolate 50 times of the medicinal materials; grinding Borneolum Syntheticum, dissolving in 95% ethanol, mixing with percolate, stirring, sealing, and standing. When in use, the traditional Chinese medicine composition is soaked in alcohol and glycerol for wet dressing, the sterile gauze soaked with the wet medicine is applied to the hematoma part, the wet dressing area exceeds the edge of the hematoma, and a disposable sterile towel is wrapped on the outer layer. Raise the limb 30 degrees below the elbow joint. Keeping the wrist joint straight, and replacing the gauze for 4h for 1 time and 2 times per day for three consecutive days.
Malignant tumor is a systemic and complex disease that seriously endangers human health, surgery is the preferred treatment for solid tumors. Due to the extensive invasion and metastasis of advanced tumors, radiotherapy and chemotherapy are the main treatment options. However, the tolerance of tumor to chemoradiotherapy often leads to treatment failure and poor prognosis. Immunotherapy provides a new approach for the systemic treatment of tumors, but the clinical efficacy is still limited. Therefore, it is important to find effective drugs to improve the tumor response to radiotherapy and immunotherapy. Previous studies by our team have found that methotrexate can activate anti-tumor immunity. The discovery of a new effect of this drug will improve tumor response to immunotherapy and prognosis of patients. The objective of this clinical trial is to explore the efficacy and safety of methotrexate combined with immunotherapy and radiotherapy in patients with unresectable/recurrence solid tumors.
Subarachnoid hemorrhage (SAH) is a severe form of stroke that can cause unpredictable and diffuse cerebral damage, which is difficult to detect until it becomes irreversible. Therefore, there is a need for a reliable method to identify dysfunctional regions and initiate treatment before permanent damage occurs. Neurobehavioral assessments have been suggested as a possible tool to detect and approximately localize dysfunctional cerebral regions. In this study, we hypothesized that a neurobehavioral assessment battery could be a sensitive and specific method for detecting damage in discrete cerebral regions following SAH. To test this hypothesis, a behavioral battery was employed at multiple time points after SAH induced via an endovascular perforation, and brain damage was confirmed via postmortem histopathological analysis. Our results demonstrate that impairment of sensorimotor function accurately predict damage in the cerebral cortex (AUC 0.905; sensitivity 81.8%; specificity 90.9%) and striatum (AUC 0.913; sensitivity 90.1%; specificity 100%), while impaired novel object recognition is a more accurate indicator of damage to the hippocampus (AUC 0.902; sensitivity 74.1%; specificity 83.3%) than impaired reference memory (AUC 0.746; sensitivity 72.2%; specificity 58.0%). Tests for anxiety-like and depression-like behaviors predict damage to the amygdala (AUC 0.900; sensitivity 77.0%; specificity 81.7%) and thalamus (AUC 0.963; sensitivity 86.3%; specificity 87.8%), respectively. This study suggests that recurring behavioral testing can accurately predict damage in specific brain regions, which could be developed into a clinical battery for early detection of SAH damage in humans, potentially improving early treatment and outcomes.
The subjects will receive Bowen Technique. The treatment session will be 3 times per week for 4 weeks for 20 minutes. The Bowen technique is a subtle and precise mobilization called Bowen moves. The mobilization is applied by using the fingers and thumbs over muscles, tendon, nerves and fascia. Only gentle non-invasive pressure is applied. A Bowen moves challenges the muscles for several seconds by the application of a gentle lateral pressure applied by the therapist thumb, against its medial edge. The muscle fibres and its fascia are disturbed from their neutral position and they are slightly stretched. The therapist apply gentle pressure towards the muscles using the skin slack available, and then rolls the thumb across the muscles and gently compressing it, the muscle will bounce back to its original position. The therapist has a sense of tissue tension, and this enables his/her to feel where stress has built up in the tissue.
Participating parents will be asked to navigate a web application that consists of (a) brief, 90-second narrative videos that encourage parent-provider communication about the vaccine and (b) personalized feedback to parents that is tailored to provide educational content in response to their concerns and be motivational in nature. Providers will provide elaborated prompts related to the vaccine when meeting with parents tailored to their concerns.
The patients would receive customized diet charts providing 30-35Kcal/ideal body wt/day and 1.5 gm protein/ideal body wt/day) describing the food items along with the quantity and approximate household measurements. Diet would be so planned for each patient keeping in mind the individual food habits and choices. This group would not receive any supplement other than the prescribed diet. Whey protein will be included in this group.
Specific antigeus or vaccines are prepared by cultivating micro-organisms in vitro on culture media and under conditions as similar as possible to those in which the micro-organisms existed in vivo.  The microbes so cultivated reproduce the antigenic properties they possessed in vivo.  The culture medium consists of a body fluid such as serum, defibrinated blood, exudate, organ or tissue extract obtained from an animal of the same species as that from which the micro-organism is obtained.  For example in the case of bovine tubercle, the micro-organisms are cultivated on a bovine medium and when the culture has grown sufficiently it is inoculated on to a normal bovine medium in a glass flask and kept at 38,5-39 DEG  C. until sufficiently developed.  The micro-organisms are then collected and made into an emulsion, preferably in absence of oxygen with water or normal saline solution, put up in ampoules and kept in the dark until the micro-organisms have died a natural death, when the emulsion is ready for use.  Traces of antiseptics e.g. formaldehyde may be added to the emulsion before sealing it into the ampoules. For the treatment of human beings three types of tubercle vaccine may be employed, i.e.  (1) a vaccine made from bovine tubercle grown on bovine media; (2) a vaccine from bovine tubercle grown on human media; and (3) a vaccine from human tubercle grown on human media. The three vaccines are mixed in varying proportions according to requirements.  The antigens may be prepared with dead or alive bacterial bodies, with an extract of the bacterial bodies or with the specific liquid on which the bacteria have grown.  The antigens may be used for preventive vaccination, therapeutic vaccination, the preparation of antitoxin and antibacterial sera and for test purposes.
Participants receive initially one session for psychological assessment. At the end of the session, the second session is scheduled for the following week, where feedback about the assessment will be provided. If in the second session participants agree to proceed with the psychological intervention, then the remaining 4-6 sessions of Skills4Parenting+ are conducted.